Case Studies

Nuclear Services Company
NASDAQ
United States

The principles of Crescendo began work with this leading provider of nuclear waste services in 2001. Since then, Crescendo has been instrumental in dramatically expanding this Client’s institutional shareholder base, which now includes many of the premier funds on Wall Street. With our assistance, the Client secured analyst coverage from leading investment banks, has been featured on CNBC and Fox News, and presented at many of the top investment banking conferences in the U.S.

Telecommunications Equipment Provider
Over-the-Counter
United States

Crescendo was retained by this Client in mid-2006, at a time when they had a very “toxic” equity financing in place with prospectively harmful reset and “make-good” provisions. Crescendo identified a long-term, micro-cap focused hedge fund to buy out the shares from the original toxic investor and replace the toxic investment with a very clean, long-term structure that enhanced the attractiveness of the company to investors and provided greater financing flexibility to execute on its operational plans. Subsequent to the refinancing, Crescendo began an aggressive and successful marketing campaign to build the Client’s shareholder base and raise additional capital on less onerous terms.

U.S. Healthcare Services SPAC
Over-the-Counter
United States

Crescendo began work with this Special Purpose Acquisition Company (SPAC) in 2007, after its IPO, but prior to the Client’s planned merger with a healthcare services company. In order to consummate the merger, the SPAC required an 80% approval vote from shareholders as is standard practice. The Client did not have the necessary support from shareholders for this transaction and hired Crescendo to find new investors to support the transaction. As a result of Crescendo’s aggressive outreach to new investors, combined with subsequent turnover in the earlier investor base, the acquisition was approved by shareholders allowing the SPAC to become an operational public company.

Infrastructure Material Company
NASDAQ
China

Crescendo began work with this Client in mid-2008 immediately following the Client’s reverse merger onto the Bulletin Board. The Client had very limited float and almost no trading – it traded on average 100 shares per week. Crescendo implemented an aggressive outreach program, in conjunction with the CFO, and arranged meetings across the U.S. As a result of these outreach efforts, the trading volume increased to over 100 thousand shares per day, and Crescendo ultimately helped the Client to successfully list on the NASDAQ.

Agricultural Distributor
Over-the Counter
China

Crescendo began work with this Client in 2009 during a turbulent period in the U.S. capital markets. Prior to working with Crescendo, several leading banks were unable to raise desired PIPE financing for the Client. Once engaged, Crescendo secured financing term sheets with several hedge funds. As a result of Crescendo’s introductions, the Client raised over $3 million allowing it to expand its distribution and enter new markets.

Lithium Ion Battery Company
NYSE Amex
China

Crescendo began work with this lithium-ion battery Client in 2009. The Client had a very limited float and shareholder base. As a result of our aggressive outreach campaign, the Client dramatically increased its institutional shareholder base and secured first time research coverage. In one year alone, the Client presented at five of the leading investment banking conferences tailored specifically for U.S. listed Chinese companies.

Battery Technology Company
Over-the-Counter
China

Crescendo began work with this Client in 2010 beginning with identifying a suitable public shell in which to merge. Crescendo helped coordinate the reverse merger working closely with the attorney and auditors. Following the reverse merger, Crescendo began an aggressive IR campaign that resulted in more than a 5-fold increase in the market value of the Client, unlocking value for existing shareholders and lowering the cost of capital by an order of magnitude for any future possible M&A transaction(s).